Public Hearing on Methamphetamine
Tuesday, August 5, 2025 from 9:00 a.m. – 3:30 p.m. (EDT)
Washington, DC
Notice
Pursuant to Rule 3.4 of the Rules of Practice and Procedure of the United States Sentencing Commission, a public hearing is scheduled for Tuesday, August 5, 2025 from 9:00 a.m. – 3:30 p.m. (EDT).
The public hearing will be held at the Thurgood Marshall Federal Judiciary Building, One Columbus Circle, N.E., in the Commissioners' Conference Room of Suite 2-500 (South Lobby). The Commission will also livestream and record the event.
The hearing is intended to provide the Commission with information from invited witnesses on methamphetamine, including its chemical structure, pharmacological effects, trafficking patterns, and community impact, and the differences, if any, between methamphetamine of varying purity levels.
Agenda and Witness Statements
Opening Remarks (9:00 a.m. – 9:15 a.m.)
Hon. Carlton W. Reeves
Chair
U.S. Sentencing Commission
Panel I. Federal Law Enforcement Observations (9:15 a.m. – 10:15 a.m.)
Jonathan P. Fairbanks
Supervisory Special Agent
Appalachian HIDTA Group Supervisor
U.S. Drug Enforcement AdministrationScott R. Oulton
Deputy Assistant Administrator
Chief of Forensics, Forensic Sciences Division
U.S. Drug Enforcement Administration<Buki Ebeigbe, Ph.D.
Pharmacologist, Diversion Control Division
U.S. Drug Enforcement Administration
Panel II. Academic Observations (10:15 a.m. – 11:00 a.m.)
Karla Wagner, Ph.D.
Professor, School of Public Health
University of Nevada, RenoJonathan P. Caulkins, Ph.D.
H. Guyford Stever University Professor
of Operations Research and Public Policy
Carnegie Mellon University
Heinz College
Break (11:30 a.m. – 11:45 a.m.)
Panel III. State and Local Law Enforcement Observations (11:15 a.m. - noon)
Mark Delaney
Special Agent in Charge, Tennessee Dangerous Drugs Task Force
Tennessee Bureau of InvestigationTimothy B. Williamson
Sergeant
Ohio State Highway Patrol and Ohio HIDTAKyle Williamson
Sergeant
San Antonio Police Department and South Texas HIDTA
Lunch Break (noon – 1:00 p.m.)
Panel IV. Pharmacology and Chemical Effects (1:00 p.m. – 1:45 p.m.)
Richard De La Garza, Ph.D.
Adjunct Professor
Department of Pharmacology
University of Texas Medical BranchJohn Mendelson, MD
Chief Medical Officer of Ria Health
Clinical Professor of Medicine
University of California, San Francisco (UCSF)
Panel V. Medical and Public Health Observations (1:45 p.m. – 2:45 p.m.)
Steven Shoptaw, Ph.D.
Director of the Center for Behavioral and Addiction Medicine
Professor in Family Medicine and Psychiatry and Biobehavioral Sciences
Vice Chair for Research in Family Medicine
UCLA Family Health CenterGavin Bart, MD, Ph.D.
Professor, Medical Discovery Team on Addiction
University of Minnesota Medical SchoolRear Admiral Christopher M. Jones, Pharm.D., Dr.P.H., M.P.H.
Director of the Center for Substance Abuse Prevention
Acting Director of the Center for Behavioral Health Statistics and Quality
Substance Abuse and Mental Health Services Administration
Panel VI. Treatment Provider Observations (2:45 p.m. – 3:30 p.m.)
Edwin C. Chapman, MD
Specialist
Internal Medicine and Addiction MedicineAmanda Jernigan, LCSW
Director of Clinical Services
Gaudenzia Addiction Treatment and Recovery Services
Adjourn
To receive updates on future events and other Commission activities, subscribe for e-mail updates. For questions regarding this notice, e-mail .pubaffairs@ussc.gov